Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Affymax Inc.

www.affymax.com

Latest From Affymax Inc.

Spain's Ferrer To Rescue Floundering US Biotech Alexza

US Inhaled CNS drug biotech Alexza looks set to be acquired by Spain’s Ferrer, the licensee of its only marketed product Adasuve outside of the US, in an all-cash offer that includes contingent value rights.

Deals Platform Technologies

All New ESRD IV Drugs Should Get Break From Medicare Payment Bundle – Amgen

CMS should not limit proposed transitional payments for IV and injectable ESRD drugs based on the current criteria for bundling, Amgen says. Company's approach could benefit its new IV caclimimetic drug candidate.

BioPharmaceutical United States

Bringing Urgency And Focus To Takeda: An Interview With Tachi Yamada

In a wide-ranging interview conducted at Elsevier’s PSA 2013 conference, Takeda’s R&D chief spoke of progress in building a global vaccine business, of the key late-stage assets that will carry the company into the next decade, and of business development priorities in the post-Nycomed era.

BioPharmaceutical Research and Development Strategies

Syndax Begins New Chapter As A Late-Stage Drug Developer

A recent influx of cash to the small biotech will allow Syndax to develop its oncology asset on its own, beginning with a Phase III trial and potentially continuing to U.S. commercialization.

BioPharmaceutical North America
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Renal System
  • Alias(es)
  • Affymax Research Institute
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Affymax Inc.
  • Senior Management
  • Jonathan M Couchman, Pres. & CEO
    Mark Thompson, CFO
  • Contact Info
  • Affymax Inc.
    Phone: (650) 812-8700
    4001 Miranda Ave.
    Palo Alto, CA 94304
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register